Opthea completes patient recruitment ahead of schedule in Phase 2b Wet AMD clinical trial

Company News

by Anna Napoli

Biotech company, Opthea (ASX:OPT) has announced that recruitment into the company's ongoing Phase 2b trial of (OPT-302) for wet age related macular degeneration is complete ahead of schedule.

As a result of the early completion the reporting of primary data from the study will now be brought forward and is expected in the fourth quarter of calendar year 2019.

The phase 2b trial is a double-masked, randomized, controlled study to investigate with the addition of Opthea's therapy offer a 6 month period improves clinical outcomes.

The trial will assess 351 patients at 113 clinical sites in the US, Europe and Israel.

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.